⚕ GalenOps field
←

SITE006-0430

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2023-08-16

AEs
7
Serious
1
Dropout signal
–

Adverse events

severe serious assessed

Grade 4 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-09-15 (study day 18); relationship: N; serious criteria: life-threatening

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-09-17 (study day 20); relationship: Y

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-21 (study day 24); relationship: N

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-10-07 (study day 40); relationship: not assessed

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-10-07 (study day 40); relationship: not assessed

mild assessed

Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-10-17 (study day 50); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-11-01 (study day 65); relationship: N

Data queries

No data queries.